Public Health

Findings show that children in early childhood are not completing their multidose vaccine series due to some structural barriers.

The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.

The FDA approved the new round of vaccines for those 12 years and older and authorized emergency use for children 6 months to 11 years of age.

Following a multicenter clinical trial, a new treatment for pneumonia caused by Acinetobacter baumannii-calcoaceticus has been approved for use in adults.

Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

The American Thoracic Society released a set of guidelines addressing the use of pulmonary rehabilitation in patients with chronic obstructive pulmonary disorder and other respiratory diseases.

Researchers sought to establish the global disease burden of sickle cell disease and its mortality rate.

This COVID-19 roundup includes coverage of the FDA’s simpler vaccination schedule and authorization of new treatment, decline in pediatric asthma diagnoses during pandemic, and a new treatment combination...

After an ongoing study, the FDA approves the first vaccine for the highly contagious respiratory virus for us in the United States.